Compared with camptothecin, Topotecan hydrochloride has lower toxicity and higher anti-tumor activity. It was approved for market in 1996 and is clinically used for the treatment of advanced colon cancer, rectal cancer, ovarian cancer and small cell lung cancer
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>Topotecan hydrochloride</strong> is a semi-synthetic topoisomerase I inhibitor derived from camptothecin. It is produced via chemical synthesis and purification. Molecular formula: C23H28ClN2O6; CAS No.: 121702-45-6.</p>
<h3>Application</h3>
<ul>
<li>Oncology manufacturing for small-cell lung cancer (SCLC) formulations.</li>
<li>Development of intravenous injectables for ovarian cancer treatment.</li>
<li>Research applications in clinical trials for refractory hematologic malignancies.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly store below -20°C to maintain stability. Handling requires PPE due to cytotoxicity. Contraindicated in severe neutropenia or pregnancy. Adhere to GMP guidelines for pharmaceutical production.</p>